S&P 500   4,291.00 (-0.20%)
DOW   33,516.77 (-0.44%)
QQQ   358.59 (+0.16%)
AAPL   171.34 (+0.38%)
MSFT   316.66 (+0.96%)
META   300.52 (-1.13%)
GOOGL   130.90 (-1.07%)
AMZN   127.51 (+1.21%)
TSLA   249.96 (+1.45%)
NVDA   435.44 (+1.06%)
NIO   9.02 (+1.23%)
BABA   86.73 (+1.39%)
AMD   103.34 (+0.56%)
T   15.03 (+0.13%)
F   12.40 (-1.27%)
MU   68.23 (+4.65%)
CGC   0.79 (-2.96%)
GE   110.58 (-1.57%)
DIS   81.05 (+1.15%)
AMC   7.93 (+1.80%)
PFE   33.13 (+3.24%)
PYPL   58.43 (+0.43%)
NFLX   376.72 (+0.10%)
S&P 500   4,291.00 (-0.20%)
DOW   33,516.77 (-0.44%)
QQQ   358.59 (+0.16%)
AAPL   171.34 (+0.38%)
MSFT   316.66 (+0.96%)
META   300.52 (-1.13%)
GOOGL   130.90 (-1.07%)
AMZN   127.51 (+1.21%)
TSLA   249.96 (+1.45%)
NVDA   435.44 (+1.06%)
NIO   9.02 (+1.23%)
BABA   86.73 (+1.39%)
AMD   103.34 (+0.56%)
T   15.03 (+0.13%)
F   12.40 (-1.27%)
MU   68.23 (+4.65%)
CGC   0.79 (-2.96%)
GE   110.58 (-1.57%)
DIS   81.05 (+1.15%)
AMC   7.93 (+1.80%)
PFE   33.13 (+3.24%)
PYPL   58.43 (+0.43%)
NFLX   376.72 (+0.10%)
S&P 500   4,291.00 (-0.20%)
DOW   33,516.77 (-0.44%)
QQQ   358.59 (+0.16%)
AAPL   171.34 (+0.38%)
MSFT   316.66 (+0.96%)
META   300.52 (-1.13%)
GOOGL   130.90 (-1.07%)
AMZN   127.51 (+1.21%)
TSLA   249.96 (+1.45%)
NVDA   435.44 (+1.06%)
NIO   9.02 (+1.23%)
BABA   86.73 (+1.39%)
AMD   103.34 (+0.56%)
T   15.03 (+0.13%)
F   12.40 (-1.27%)
MU   68.23 (+4.65%)
CGC   0.79 (-2.96%)
GE   110.58 (-1.57%)
DIS   81.05 (+1.15%)
AMC   7.93 (+1.80%)
PFE   33.13 (+3.24%)
PYPL   58.43 (+0.43%)
NFLX   376.72 (+0.10%)
S&P 500   4,291.00 (-0.20%)
DOW   33,516.77 (-0.44%)
QQQ   358.59 (+0.16%)
AAPL   171.34 (+0.38%)
MSFT   316.66 (+0.96%)
META   300.52 (-1.13%)
GOOGL   130.90 (-1.07%)
AMZN   127.51 (+1.21%)
TSLA   249.96 (+1.45%)
NVDA   435.44 (+1.06%)
NIO   9.02 (+1.23%)
BABA   86.73 (+1.39%)
AMD   103.34 (+0.56%)
T   15.03 (+0.13%)
F   12.40 (-1.27%)
MU   68.23 (+4.65%)
CGC   0.79 (-2.96%)
GE   110.58 (-1.57%)
DIS   81.05 (+1.15%)
AMC   7.93 (+1.80%)
PFE   33.13 (+3.24%)
PYPL   58.43 (+0.43%)
NFLX   376.72 (+0.10%)
NASDAQ:GALT

Galectin Therapeutics (GALT) Insider Trading & Ownership

$1.91
+0.01 (+0.49%)
(As of 03:30 PM ET)
Compare
Today's Range
$1.85
▼
$1.95
50-Day Range
$1.38
▼
$1.97
52-Week Range
$1.02
▼
$2.47
Volume
32,324 shs
Average Volume
69,692 shs
Market Capitalization
$113.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Galectin Therapeutics (NASDAQ:GALT) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
44.70%
Number Of
Insiders Buying
(Last 12 Months)
4
Amount Of
Insider Buying
(Last 12 Months)
$26,793.42
Number Of
Insiders Selling
(Last 12 Months)
0
Get GALT Insider Trade Alerts

Want to know when executives and insiders are buying or selling Galectin Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

GALT Insider Buying and Selling by Quarter


Galectin Therapeutics Insider and Congressional Trades History

Export to Excel
Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/19/2023Kary EldredDirectorBuy1,598$1.79$2,860.42  
2/21/2023Kary EldredDirectorBuy1,000$1.59$1,590.00  
2/16/2023Joel LewisCEOBuy1,000$1.52$1,520.00  
1/25/2023Kary EldredDirectorBuy1,300$1.11$1,443.00  
11/17/2022Jack W CallicuttCFOBuy4,000$1.32$5,280.00  
10/28/2022Kevin D FreemanDirectorBuy10,000$1.41$14,100.00  
(Data available from 1/1/2013 forward)












GALT Insider Trading Activity - Frequently Asked Questions

Who is on Galectin Therapeutics's Insider Roster?

The list of insiders at Galectin Therapeutics includes Elissa J Schwartz, Fund L.P. 10X, Gilbert F Amelio, Jack W Callicutt, Joel Lewis, Kary Eldred, Kevin D Freeman, and Richard A Jr. Zordani. Learn more on insiders at GALT.

What percentage of Galectin Therapeutics stock is owned by insiders?

44.70% of Galectin Therapeutics stock is owned by insiders. Learn more on GALT's insider holdings.

Which Galectin Therapeutics insiders have been buying company stock?

The following insiders have purchased GALT shares in the last 24 months: Elissa J Schwartz ($2,000.00), Jack W Callicutt ($5,280.00), Joel Lewis ($1,520.00), Kary Eldred ($5,893.42), Kevin D Freeman ($73,630.00), and Richard A Jr. Zordani ($30,600.00).

How much insider buying is happening at Galectin Therapeutics?

Insiders have purchased a total of 61,898 GALT shares in the last 24 months for a total of $118,923.42 bought.

Which Galectin Therapeutics insiders have been selling company stock?

The following insider sold GALT shares in the last 24 months: Fund L.P. 10X ($167,500.00).

How much insider selling is happening at Galectin Therapeutics?

Insiders have sold a total of 60,000 Galectin Therapeutics shares in the last 24 months for a total of $167,500.00 sold.


More Insider Trading Tools from MarketBeat

Related Companies:
Insider Tracking Tools:
Insider Trading By Country:
Latest Articles:
This page (NASDAQ:GALT) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -